Multimodal Therapy for Gastric or Gastroesophageal Junction Adenocarcinoma -ECF vs. FLOT

被引：0
|
作者：
Schroeder, W. [1 ]
Bruns, C. J. [1 ]
机构：
[1] Univ Klin Koln, Klin Allgemein Viszeral & Tumorchirurg, Kerpener Str 62, D-50937 Cologne, Germany
来源：
CHIRURG | 2019年 / 90卷
关键词：
D O I：
10.1007/s00104-019-0841-4
中图分类号：
R61 [外科手术学];
学科分类号：
摘要：
引用
收藏
页码：S27 / S27
页数：1
相关论文
共 50 条
  • [41] Efficacy and side effects of pembrolizumab plus chemotherapy vs. chemotherapy alone in patients with advanced gastric or gastroesophageal junction adenocarcinoma: A meta-analysis
    Li, Jinquan
    Hu, Xiaosheng
    Zhang, Shanzhong
    ONCOLOGY LETTERS, 2024, 28 (02)
  • [42] Oxaliplatin in perioperative chemotherapy for gastric and gastroesophageal junction (GEJ) adenocarcinoma
    Fritsch, Ralph
    Hoeppner, Jens
    EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2019, 13 (04) : 285 - 291
  • [43] Distinct differences in genomic profile of gastric and gastroesophageal junction adenocarcinoma
    Nakauchi, Masaya
    Walch, Henry S.
    Chatila, Walid Khaled
    Thinh Tran
    Vos, Elvira Lise
    Sihag, Smita
    Tang, Laura H.
    Coit, Daniel G.
    Stadler, Zsofia Kinga
    Janjigian, Yelena Y.
    Maron, Steven Brad
    Ku, Geoffrey Yuyat
    Ilson, David H.
    Solit, David B.
    Schultz, Nikolaus
    Molena, Daniela
    Strong, Vivian E.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [44] Synchronous Gastroesophageal Junction and Gastric Adenocarcinoma in an Otherwise Healthy Male
    Agulto, Aireen
    Chela, Harleen K.
    Hammoud, Ghassan
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2022, 117 (10): : S2306 - S2307
  • [45] Chemotherapy and Immune Checkpoint Blockade for Gastric and Gastroesophageal Junction Adenocarcinoma
    Manji, Gulam A.
    Lee, Shing
    Del Portillo, Armando
    May, Michael
    Ana, Sarah Sta
    Alouani, Emily
    Sender, Naomi
    Negri, Tiffany
    Gautier, Katarzyna
    Ge, Liner
    Fan, Weijia
    Xie, Mengyu
    Sethi, Amrita
    Schrope, Beth
    Tan, Aik Choon
    Park, Haeseong
    Oberstein, Paul E.
    Shah, Manish A.
    Raufi, Alexander G.
    JAMA ONCOLOGY, 2023, 9 (12) : 1702 - 1707
  • [46] Neoadjuvant chemoimmunotherapy in locally advanced gastric or gastroesophageal junction adenocarcinoma
    Liu, Xiao
    Ma, Baozhen
    Zhao, Lingdi
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [47] The Role of Radiation Therapy for Resectable Adenocarcinoma of the Gastroesophageal Junction
    Al-Batran, Salah-Eddin
    ONCOLOGIST, 2014, 19 (04): : 431 - 431
  • [48] Efficacy and safety of camrelizumab combined with FLOT versus FLOT alone as neoadjuvant therapy in patients with resectable locally advanced gastric and gastroesophageal junction adenocarcinoma who received D2 radical gastrectomy: Data update.
    Liu, Zimin
    Liu, Ning
    Zhou, Yanbing
    Niu, Zhaojian
    Jiang, Haitao
    Zhu, Yingqian
    Wang, Huiyun
    Li, Xiaoxiao
    Song, Shanai
    Liu, Xiaodong
    Li, Zequn
    Zhao, Shufen
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E16044 - E16044
  • [49] Preventive HIPEC in combination with perioperative FLOT versus FLOT alone for resectable diffuse type gastric and gastroesophageal junction type II/III adenocarcinoma - the phase III "PREVENT"-(FLOT9) trial of the AIO/CAOGI /ACO
    Goetze, Thorsten O.
    Piso, Pompiliu
    Lorenzen, Sylvie
    Bankstahl, Ulli S.
    Pauligk, Claudia
    Elshafei, Moustafa
    Amato, Giuseppe
    Reim, Daniel
    Bechstein, Wolf O.
    Koenigsrainer, Alfred
    Moenig, Stefan P.
    Rau, Beate
    Schwarzbach, Matthias
    Al-Batran, Salah-Eddin
    BMC CANCER, 2021, 21 (01)
  • [50] Preventive HIPEC in combination with perioperative FLOT versus FLOT alone for resectable diffuse type gastric and gastroesophageal junction type II/III adenocarcinoma – the phase III “PREVENT”- (FLOT9) trial of the AIO /CAOGI /ACO
    Thorsten O. Götze
    Pompiliu Piso
    Sylvie Lorenzen
    Ulli S. Bankstahl
    Claudia Pauligk
    Moustafa Elshafei
    Giuseppe Amato
    Daniel Reim
    Wolf O. Bechstein
    Alfred Königsrainer
    Stefan P. Mönig
    Beate Rau
    Matthias Schwarzbach
    Salah-Eddin Al-Batran
    BMC Cancer, 21
12345